Blog

Hello November. Desk calendar for planning November 2025.

Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences.1. Regulatory &amp; Policy: The "AI Act Pause" ProposalThe most significant strategic development this week is the European Commission's proposal to delay the enforcement of "high-risk" AI rules for medical devices. The News: As part of a new "Digital Omnibus" package introduced this week, the Commission has proposed a "targeted implementation delay" for the EU AI Act. Impact: This would effectively pause the enforcement of strict obligations for high-risk AI systems (which includes many AI-driven medical devices) that were set to apply from August 2026. Why it matters: MedTech industry groups have been lobbying for this, arguing that the "dual regulatory burden" of complying with both the Medical Device Regulation (MDR) and the new AI Act would stifle innovation. If passed, this gives manufacturers a critical breathing room of up to 16 months to align their technical standards. 2. Investment &amp; FundingA €650M Boost Despite a generally difficult fundraising climate, this week saw a massive commitment to the European life sciences ecosystem.Sofinnova Partners closes Capital XI: The Paris-based venture capital firm announced the final close of its "Capital XI" fund at €650 million ($750M). Focus: The fund is specifically targeted at early-stage biotech and MedTech companies. This is a strong signal of investor confidence in European deep-tech and medical innovation, providing much-needed liquidity for startups facing the "series A crunch." 3. Major Events: Medica &amp; Helsinki Summit Europe hosted two pivotal industry gatherings this week, driving networking and partnership announcements. MEDICA 2025 (Düsseldorf, Nov 17–20): One of the world's largest medical trade fairs concluded yesterday. Key themes this year included "Hospital 4.0," sustainable manufacturing, and the integration of generative AI into clinical workflows. MedTech Innovation Helsinki Summit (Nov 19): This high-profile summit focused on bridging the gap between Nordic innovation and global capital. Highlight: The event featured a pitch competition with a €300,000 investment prize, hosted in partnership with Global Medical Solutions and Samsung Medical. The event underscored the growing role of corporate venture capital (CVC) in the European market. 4. Product &amp; Corporate Moves Zydus Lifesciences (CE Mark): While announced just prior to this week, the industry is currently digesting the impact of Zydus' subsidiary, Amplitude Surgical, receiving the CE Mark for its "Andy" robotic surgical system. This clears the way for a new competitor in the European orthopaedic robotics market, challenging established US players. Global M&amp;A Ripples: The sector is also reacting to Abbott’s massive $21 billion acquisition of Exact Sciences(announced earlier but dominating discussion at Medica). For European MedTech, this consolidation signals likely intensified competition in the non-invasive cancer diagnostics space across the continent. &nbsp; &gt;&gt;&gt;&nbsp; &nbsp; European HealthTech (digital health, data and AI) developments for the week of November 17–21, 2025 are detailed below. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability. 1. Regulation &amp; Policy: A Double-Edged Sword for AIThe biggest structural shift for European HealthTech occurred on Wednesday, November 19, with the European Commission's "Digital Omnibus" proposal. The "Data Unlock" (GDPR Reform): Beyond the AI Act delay, the most critical update for HealthTech is a proposed change to GDPR. The Commission wants to classify "training AI models" as a "legitimate interest." Why this matters: Currently, HealthTech startups often struggle to use patient data to train algorithms without explicit, granular consent. If passed, this amendment could significantly lower the legal barrier for accessing real-world data (RWD) to build predictive models. The Counterpoint (WHO Warning): coinciding with this deregulation push, the World Health Organization (Europe) released a report this week warning of a "regulatory vacuum" regarding AI liability. They cautioned that while tools are being adopted rapidly, it remains unclear who is legally responsible, the software provider or the clinician, when an AI diagnostic tool makes an error. 2. Investment: FemTech &amp; UK Life SciencesWhile mega-rounds were quieter this week compared to earlier in the month (e.g., Qida’s €37M raise was Nov 4), specialized sectors saw fresh activity. Emm (UK) raises €7.7M: Bristol-based FemTech startup Emm secured €7.7M ($9M) in Seed funding on November 19. The Tech: They are developing a "smart menstrual cup" that uses biosensors to monitor health metrics remotely. This highlights a growing trend of "invisible" wearables that passively collect clinical-grade data. UK Government &amp; Sofinnova: As part of a broader life sciences package announced Nov 18, the British Business Bank committed €30 million specifically to Sofinnova’s new fund. This capital is earmarked for high-growth digital and biotech ventures, reinforcing the UK's post-Brexit push to remain a top hub for health innovation. 3. Innovation Highlight: AI in Practice (Ireland) The AI Awards Ireland (Nov 18) provided a look at which HealthTech solutions are gaining traction on the ground right now: Best AI in a Startup: Won by WHYZE Health, a platform that uses AI to match patients with clinical trials using real-world evidence. This addresses a major bottleneck in European pharma: slow patient recruitment. Clinical Efficiency: St. Luke’s Radiation Oncology Network won for an AI tool that automates "contouring" (outlining tumours) for radiation therapy. The system reportedly reduces manual planning time by 50%, a concrete example of AI relieving workforce burnout. 4. Ecosystem &amp; Events European Digital Health Literacy Conference (Aalborg, Nov 17-18): This inaugural conference focused on the "human side" of HealthTech adoption. A key takeaway was the "digital divide", new EU data suggests that while apps are proliferating, elderly adoption remains stalled due to poor UX design, prompting calls for new "age-inclusive" software standards. Danish Tech in Silicon Valley: A delegation of Danish HealthTech startups is currently in Palo Alto (Nov 17-21) for the "Plug and Play" summit, actively seeking US commercial partners to scale European digital solutions transatlantic.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a> &nbsp;

This Week in European HealthTech and MedTech: 21st November 2025

Nelson Advisors have been invited to Chair the 'Finance in Healthcare: Pathways from VC to PE through M&amp;A Event' for the Healthcare Club at the IESE Business School, Barcelona in December 2025.<a data-mce-href="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" href="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" title="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" target="_blank" rel="noopener">https://groups.iese.edu/healthcare/rsvp_boot?id=300117522</a> The Founding Partners of Nelson Advisors believe strongly in sharing their experiences and knowledge of the HealthTech and MedTech markets with students across a wide range of UK and European Universities ranging from Oxford University and University of Cambridge to London Business School and University College London Global Business Schood for Health to IESE Business School. &nbsp;&nbsp; IESE Business School &nbsp;&nbsp; IESE Business School is the graduate business school of the University of Navarra, with its main campus located in Barcelona, Spain. It is consistently ranked among the top business schools globally, particularly for its MBA and Executive Education programs. &nbsp;&nbsp; Key Characteristics &nbsp;&nbsp; Global Mindset: IESE has a strong international focus with a highly diverse student body and campuses in Barcelona, Madrid, New York, Munich, and São Paulo.Case Method: The school is well-known for its extensive use of the case method, a teaching approach that uses real-world business problems to develop students' critical thinking, problem-solving, and decision-making skills.Values-Based Leadership: IESE emphasises a people centred vision and a commitment to ethics and social responsibility, aiming to educate leaders who can have a positive impact on business and society. &nbsp;&nbsp; Programmes &nbsp;&nbsp; IESE offers a variety of programs, including: &nbsp;&nbsp; Full-time MBA: A 15- or 19-month program known for its global approach. The curriculum includes core courses in the first year and a wide selection of electives in the second.&nbsp;Executive MBA (EMBA): A part-time program designed for experienced professionals.Global Executive MBA (GEMBA): A blended program with on-campus and online components.Executive Education Programs: These are consistently ranked among the best in the world and are aimed at functional managers, senior executives, and C-suite leaders. &nbsp;&nbsp; Rankings and Reputation &nbsp;&nbsp; IESE's programs are highly regarded in international rankings. Recent rankings include: &nbsp;&nbsp; Financial Times Global MBA Ranking: Consistently ranked in the top 10, with a #3 ranking in 2025.The Economist Full-time MBA Ranking: Ranked #1 in the world in 2021.Financial Times Executive Education: Ranked #1 for six consecutive years (2015-2020) and continues to be highly ranked.The school holds triple accreditation from AACSB, AMBA, and EQUIS. &nbsp;&nbsp; IESE Business School &gt; Healthcare Club &nbsp;&nbsp; The IESE Business School Healthcare Club is a professional student club at IESE that focuses on the healthcare industry. Its mission is to support IESE students who are interested in pursuing a career in healthcare by providing them with the resources, knowledge, and networking opportunities they need. &nbsp;&nbsp; The club's activities are designed to help students: &nbsp;&nbsp; Learn about the healthcare sector: They organize seminars, workshops, and panels with industry experts, IESE professors, and alumni. These events cover various aspects of the healthcare industry, from pharmaceuticals and medical devices to digital health and healthcare consulting.Network with industry professionals: The club facilitates connections with leading healthcare companies, startups, and alumni. They host networking events, company visits, and an annual "Healthcare Day" conference, which brings together top professionals to discuss current trends and challenges in the industry.Find a job in the healthcare sector: The club offers career support through CV/cover letter workshops, interview preparation, and a mentorship program that connects students with experienced professionals. They also organize career treks to major healthcare hubs like Basel, Switzerland, and Madrid, Spain, where students can visit companies and network with potential employers.The IESE Healthcare Club plays a key role in positioning the IESE MBA as a source of top talent for healthcare companies and is a valuable resource for students aiming to transition into or advance their careers in this dynamic and impactful industry.

Nelson Advisors invited to Chair the panel at IESE Business School event - Finance in Healthcare: Pathways from VC to PE through M&A

Nelson Advisors Partner Lloyd Price has been invited to speak at the Leaders in Health Summit 2025 in London and debate the 'Business Case for Ultra Personalisation'&nbsp;Event Details &nbsp;&nbsp; Date: Tuesday, November 18, 2025 &nbsp;&nbsp; Location: Havas Kings Cross Building, London &nbsp;&nbsp; Host: WellFounded (Founders Health &amp; Concierge Performance Medicine) &nbsp;&nbsp; Access: By invitation/application only (free for invited guests/applicants) &nbsp;&nbsp; Source: https://wellfounded.health/summit-schedule &nbsp;&nbsp; Core Theme &nbsp;&nbsp; The overarching question driving the Summit is: "Can Precision Breakthroughs, Regulatory Revolution &amp; AI (Re)Humanise Healthcare?"The goal is to explore how to "Make medicine personable again."Key Areas of Focus (The Deeper Shift) &nbsp;&nbsp; The summit is dedicated to exploring the fundamental reimagining of medicine around the individual, moving beyond just diagnostics and treatment. The topics include: &nbsp;&nbsp; Direct-to-Customer Preventive Services: Exploring the business models and innovations in consumer health that are attracting significant investment and moving care away from traditional clinical settings.Concierge Practices &amp; Human-Centred Care: Discussing new models of healthcare delivery that promise deeply personalised, high-touch, human-centred care.Longevity Clinics: Examining the radically tailored pathways and scientific developments offered by longevity and healthspan clinics.AI Redefining Medicine: Analysing how Artificial Intelligence is fundamentally changing the way patients and clinicians interact with medicine.The Fifth 'P': Personable: Moving beyond Professor Leroy Hood's "4P's" (Proactive, Precise, Preventive, Personalised) to address the need to make healthcare truly Personable.Critical DebatesThe Summit will also delve into the complexities and challenges of this transformation, with provocations such as: &nbsp;&nbsp; Is AI an efficiency tool that buys the profession more time, or is it dissolving the essential clinician–patient bond?Are customised therapies, biotech breakthroughs, and loosely regulated trials truly testable and scalable for the wider population?The event is designed to bring a "human lens" to the future of healthcare, from hyper-targeted treatments to achieving human flourishing.&gt;&gt;To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk﻿</a>

Nelson Advisors invited to speak at the Leaders in Health Summit 2025 and debate the 'Business Case for Ultra Personalisation'

complex messy management, organization and innovation, chaotic decision tree, complicated business process

The process from pitching an idea ("Board") to its widespread use by clinicians and patients ("Ward") in HealthTech and MedTech is a multi-stage Health Technology Pathway focused on demonstrating value, ensuring safety, and securing buy-in. It is typically non-linear and requires constant engagement with diverse stakeholders.Here is an overview of the key phases:1. Idea Creation and Value Proposition (The Pitch) 💡 This initial phase establishes the foundation for the technology.Identify the Unmet Need: The process begins with identifying a clear problem or gap in clinical care that the proposed technology (device or digital solution) can solve. This must be a patient-centric need. Concept &amp; Development: The technology is designed with the end-user (clinicians and patients) in mind to ensure an intuitive and seamless experience that doesn't disrupt workflow. Value Proposition: A clear statement is developed to explain the benefits to the healthcare system, clinicians, and patients. This typically includes improvements in patient outcomes, cost-effectiveness, and/or operational efficiency. Early Engagement: Innovators engage early with key stakeholders, including regulators, commissioners, and patient groups, to align the technology's design and evidence requirements with the needs of the healthcare system.&nbsp;2. Regulatory Approval and Evidence Generation (The Validation) ✅ This is the critical phase where the technology is tested and formally approved for use.Clinical Trials/Testing: Rigorous studies are conducted to generate clinical evidence demonstrating the safety and effectiveness of the solution. This is essential for regulatory and adoption decisions. Regulatory Approval: The technology must meet stringent regulatory standards (e.g., FDA in the US, MHRA in the UK, MDR/IVDR in the EU) to be classified and marketed as a medical device or digital health solution. This often involves a risk-based approach, with higher-risk devices requiring more rigorous review. Health Technology Assessment (HTA): Independent bodies (like NICE in the UK) assess the clinical and cost-effectiveness of the technology compared to existing standard care. A positive HTA recommendation is often a prerequisite for national funding and commissioning. Post-Market Surveillance Planning: A plan is established for ongoing monitoring of the device's safety and performance once it's in use. 3. Funding, Commissioning, and Implementation (The Adoption) 🏥 Once the technology is proven safe and effective, the focus shifts to securing funding and integrating it into clinical practice.Funding and Procurement: The technology must secure a clear funding or reimbursement pathway. This involves navigating complex procurement routes and demonstrating the long-term value for money to health system commissioners. Commissioning and Local Planning: Healthcare organizations (e.g., Integrated Care Systems) decide to purchase and integrate the technology. This involves thorough mapping of existing clinical workflows to identify necessary process changes. Implementation &amp; Pilot Programs: A phased rollout is typically recommended, starting with pilot programs in specific departments or hospitals. This allows for real-world testing, gathering user feedback, and refining the implementation plan before a full-scale launch. Clinical Champion Buy-in: Identifying and empowering clinical champions—doctors, nurses, or other clinicians who are enthusiastic about the technology—is crucial. They drive local change, train peers, and provide essential feedback. 4. Clinician and Patient Adoption (The Ward) 🤝 The final stage ensures the technology is routinely and effectively used by its target users.Training and Support: Comprehensive, tailored training is provided to all end-users (clinicians, administrative staff, and patients). Ongoing, easily accessible support is vital to address issues as they arise. User-Centric Design: Technology adoption is significantly improved if the solution is intuitive and demonstrably saves the user time or significantly enhances patient care, rather than just adding to their workload. Continuous Feedback Loop: A mechanism for collecting and acting on feedback from frontline clinicians and patients must be established. This allows for iterative improvements to the product and the local implementation process. Measuring Outcomes: Organizations continuously monitor key performance indicators (KPIs) to ensure the technology delivers the promised benefits (e.g., reduced waiting lists, improved patient safety, better treatment outcomes). Cultural Change: Successful adoption requires overcoming system inertia and building a culture where innovation is valued and embedded into routine practice across the organization—the true "Board to Ward"culture.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Board to the Ward : Multi Stage  HealthTech and MedTech Pathway

November 2025 Calendar On Blue Background

Major European MedTech Developments (Week of Nov 10 - Nov 14, 2025) &nbsp;&nbsp; 1. Key Regulatory Milestone: CE Mark for Surgical Robotics &nbsp;&nbsp; The most significant development is a major market access approval: &nbsp;&nbsp; Zydus Lifesciences' 'Andy' Robotic Surgical System received the CE Mark approval.Implication: This approval validates its compliance with European safety standards and opens up market opportunities in the European Union for the system, which combines navigation technology with robotic assistance for orthopaedic surgeries (knee and hip). This reflects the growing focus on advanced surgical robotics in Europe. &nbsp;&nbsp; 2. Industry Spotlight: MedTech World Malta 2025 &nbsp;&nbsp; The MedTech world's attention has been on the major conference held this week: &nbsp;&nbsp; Event: MedTech World Malta 2025 took place, gathering over 2,000 global industry leaders, investors, and innovators.Government Focus: The Prime Minister of Malta highlighted a national ambition for Malta to become a leading European hub for MedTech, Life Sciences, and Digital Health, emphasising public-private partnerships, AI-driven healthcare projects, and investor interest.Activity:&nbsp; &nbsp;&nbsp; The event featured the MedTech World StartUp Pitch and workshops, indicating a strong focus on connecting emerging innovation with investment. &nbsp;&nbsp; 3. Regulatory Discussion: Navigating the EU AI Act &nbsp;&nbsp; Regulatory compliance for digital health remains a major topic: &nbsp;&nbsp; Concern: Experts at the European Digital Technology and Software conference expressed concerns that the recently enacted EU Artificial Intelligence (AI) Act poses a significant burden on new AI-enabled MedTech products.Industry Hope:&nbsp; &nbsp;&nbsp; There is an expectation that the European Commission's upcoming Digital Omnibus may provide some relief or clarity, potentially leading to delays in the strict implementation deadlines for AI-enabled healthcare products to allow manufacturers to catch up. &nbsp;&nbsp; 4. Investment and Funding &nbsp;&nbsp; While not a new deal this week, the investment climate is still dominated by a significant October venture loan: &nbsp;&nbsp; EIB Backing: The European Investment Bank (EIB) recently provided a €20 Million venture loan to German MedTech company PRECISIS GmbH.Focus: This funding is to support the further clinical development and international expansion of their EASEE® neuro stimulation therapy for drug-resistant epilepsy, which has been CE-certified since 2022 and is already in use across six European countries. &nbsp;&nbsp; In summary, the European MedTech sector this week saw a significant market entry for a new surgical robot, a major industry conference focusing on Malta as a future hub, and ongoing high-level discussions around the impact and implementation of the new AI Act on digital health products. &nbsp;&nbsp; &gt;&gt;&gt; &nbsp;&nbsp; Digital Health/HealthTech is currently driving much of the innovation in European healthcare.Building on the developments from this week, here are the major highlights specifically within the European HealthTech sector: &nbsp;&nbsp; Major European HealthTech Developments (Week of Nov 10 - Nov 14, 2025) &nbsp;&nbsp; The key themes this week are the European Union's regulatory simplification push and a strong, specialised investment focus on AI and chronic care. &nbsp;&nbsp; 1. EU Regulatory Movement: Digital Simplification Package &nbsp;&nbsp; The biggest news is the anticipated release of the European Commission's "Digital Package on Simplification," expected on November 19th. Focus: Leaked proposals indicate a major attempt to simplify and harmonize several existing digital laws that impact HealthTech, including GDPR, ePrivacy, and the AI Act. HealthTech Impact: &nbsp;&nbsp; AI Act Easing: There is ongoing debate and pressure (from both US and European tech companies) to delay the application of certain compliance deadlines for the High-Risk AI Systems classification. The industry hopes this delay will provide more time for digital health companies to meet the stringent requirements without stifling innovation. &nbsp;&nbsp; Data Reporting: Proposals suggest a lighter reporting regime for personal data breaches, allowing for a higher threshold for mandatory reporting and increasing the reporting window to 96 hours, which would ease the burden on HealthTech providers. &nbsp;&nbsp; Cookie Consent: Long-term plans advocate for moving away from repetitive cookie banners to universal, settings-based mechanisms for user preferences, which would streamline the patient experience on digital health platforms. &nbsp;&nbsp; 2. Targeted Investment &amp; Funding &nbsp;&nbsp; European investors are moving capital into specialised, scalable digital care models: &nbsp;&nbsp; Elder-Care Funding: Spanish HealthTech startup Qida secured a massive €37 Million funding round. This is noted as the largest investment ever in the elder-care sector in Spain, signalling a significant, growing investor appetite for tech-enabled home and long-term care models across the continent. &nbsp;&nbsp; Chronic Care Focus: The investment landscape continues to prioritise proven business models, with a recent focus on digital clinics for chronic conditions (such as obesity and epilepsy), which demonstrate clear patient value and reimbursement pathways. &nbsp;&nbsp; 3. AI in Practice and Policy &nbsp;&nbsp; AI is rapidly moving into real-world clinical application: &nbsp;&nbsp; Ambient AI for Clinicians: The launch of tools like Keikku 2.0 (a digital stethoscope with integrated AI Scribe) highlights the immediate demand for AI that automates documentation and assists diagnostics at the point of care, freeing up physician time. &nbsp;&nbsp; WHO/Europe AI Summit: Looking ahead, WHO/Europe and the Government of Malta are co-hosting a high-level meeting on November 19th titled "AI for Health and Care in Europe," aiming to launch a new regional report and explore practical, country-level solutions for ethical and responsible AI implementation in national health systems. &nbsp;&nbsp; EU HTA Regulation (Future Impact): The upcoming implementation of the new Health Technology Assessment (HTA) Regulation in 2025 is a long-term development that will significantly impact HealthTech. The regulation's goal is to unify clinical assessments across the EU, which will ultimately streamline how digital therapeutics and AI-driven diagnostics achieve reimbursement and market access in member states.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech and MedTech: 14th November 2025

The Mergers and Acquisitions (M&amp;A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions.&nbsp; &nbsp;&nbsp; This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinations.&nbsp; &nbsp;&nbsp; The single most potent catalyst driving deal value across both sectors is the urgent necessity to acquire advanced Artificial Intelligence (AI) and Generative AI (GenAI) capabilities, crucial for driving operational efficiency, streamlining workflows, and mitigating persistent margin compression. &nbsp;&nbsp; The market dynamic is shifting from a focus purely on innovation to one demanding demonstrable return on investment (ROI) derived from technological integration. Private Equity (PE) involvement remains high, supported by robust dry powder reserves, with sponsors focusing on both platform expansion and realising delayed exits into a receptive corporate buyer market."MedTech M&amp;A in 2026 will be characterised by aggressive moves to secure high-growth niches, integrate next-generation technology, and strategically manage portfolio risk, particularly in response to the GLP-1 drug phenome.""HealthTech M&amp;A in 2026 is fundamentally an infrastructure play, where AI and GenAI capabilities are acquired to automate and optimise the administrative and clinical workflows that account for a disproportionate amount of healthcare costs."Source: <a data-mce-href="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" href="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" title="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

This Week in European HealthTech and MedTech: 21st Novemb...

Nelson Advisors invited to Chair the panel at IESE Busine...

Nelson Advisors invited to speak at the Leaders in Health...

Board to the Ward : Multi Stage HealthTech and MedTech P...

This Week in European HealthTech and MedTech: 14th Novemb...

The 2026 HealthTech and MedTech Deal Thesis